Valeo Pharma receives the Canadian rights to market new severe anaphylactic reaction device

Under the agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT in Canada for an initial 10-year period.

This article is related to Canada’s biotechnology and pharmaceutical manufacturing Industries. Alfa Laval's Heat Transfer, Separation and Hygienic Fluid Handling products are used by pharmaceutical manufacturers across Canada.

 

View the full article on canadianmanufacturing.com

 

“…Valeo Pharma Inc. has entered into a license, supply, and commercialization agreement with Kaléo Inc. for the Canadian rights to ALLERJECT, an auto-injector for the treatment of serious allergic reactions...

 

…With the Canadian market for epinephrine auto-injectors exceeding $80 million per year, we believe that ALLERJECT’s peak sales potential exceeds $25 million…

 

…According to ALLERJECT, over 700,000 people are estimated to be at risk for anaphylaxis due to food or insect stings alone at least once in their lifetime...”

 

Click here to learn more about Alfa Laval’s food grade pumps, valves, heat exchangers and separators for hygienic applications.